GlassScriptPhysician profile
Jordyn Manuel
NPI 1598424632
$2,368.50
in general payments reported to CMS, 2019-2025
31 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $97.17 · 2024: $503 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $276.95 | 2024-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $233.63 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $228.62 | 2024-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $212.36 | 2024-2025 | Acthar, Terlivaz |
| Medtronic, INC. | $211.94 | 2022-2023 | Ellipsys Vascular Access System, Chameleon |
| Fresenius USA Marketing, INC. | $146.41 | 2024-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $85.30 | 2025 | Veltassa |
| Ani Pharmaceuticals, INC. | $81.44 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $77.08 | 2025 | |
| Nxstage Medical, INC. | $75.76 | 2025 | Nxstage System One |
| Novo Nordisk INC | $71.45 | 2024-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $57.70 | 2024-2025 | Injectafer |
| Lilly USA, LLC | $56.40 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $45.18 | 2025 | Farxiga |
| Bard Peripheral Vascular, INC. | $40.65 | 2023 | Rotarexs 6 F X 135 Cm |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $39.73 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $37.93 | 2024-2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $37.88 | 2025 | Ultomiris |
| Akebia Therapeutics INC | $37.56 | 2025 | Vafseo |
| Boston Scientific Corporation | $36.95 | 2024 | Varithena Administration Pack |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.07 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $34.36 | 2025 | Ibsrela |
| Amgen INC. | $32.96 | 2025 | Tavneos |
| Convatec INC. | $30.65 | 2022 | |
| Abbott Laboratories | $29.82 | 2024 | Diamondback Peripheral |
| Terumo Medical Corporation | $24.80 | 2024 | Angio-Seal |
| Scpharmaceuticals INC. | $19.75 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.62 | 2025 | |
| Chiesi USA, INC. | $17.91 | 2025 | Elfabrio |
| Aurinia Pharma U.S., INC. | $16.46 | 2025 | Lupkynis |
| Cormedix INC. | $15.18 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordyn Manuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.